<DOC>
	<DOC>NCT02005159</DOC>
	<brief_summary>Provide scientific and validated data to help International Authorities to set susceptible to antibiotics cut-off points in bacteremia by Enterobacteriaceae</brief_summary>
	<brief_title>Study of the Impact of the Minimum Inhibitory Concentration and Susceptible Cut-off Points (CLSI, EUCAST, and Pharmacokinetics/Pharmacodynamics)in Prognosis of Bacteremia by Enterobacteriaceae</brief_title>
	<detailed_description />
	<mesh_term>Bacteremia</mesh_term>
	<mesh_term>Mitomycin</mesh_term>
	<mesh_term>Ifosfamide</mesh_term>
	<mesh_term>Cisplatin</mesh_term>
	<criteria>&gt;17 years old Clinically significant bacteremia Have received treatment fulfilling all this criteria: 1. Treated with an only active antibiotic with enterobacteria (association with vancomycin, linezolid, daptomycin, metronidazole or clindamycin) between: cefotaxime, ceftriaxone, ceftazidime, cefepime, amoxicillin/clavulanic, piperacillin/tazobactam, ertapenem, imipenem, meropenem, ciprofloxacin or levofloxacin 2. First antibiotic dose was administered during the first 12 hours after the time of sampling 3. The antibiotic dosage was at least the advised amount in the summary of product characteristics to patient renal function 4. The same antibiotic has been administered during at least 48 hours.</criteria>
	<gender>All</gender>
	<minimum_age>17 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>August 2015</verification_date>
	<keyword>Enterobacteria</keyword>
	<keyword>Bacteremia</keyword>
	<keyword>Minimum inhibitory concentration</keyword>
	<keyword>Susceptible</keyword>
	<keyword>Prognosis</keyword>
</DOC>